GnRH agonist versus recombinant HCG in an oocyte donation programme: A randomized, prospective, controlled, assessor-blind study

Reproductive BioMedicine Online

Volumn 19, Issue 4, 2009, Pages 486-492

  Melo, Marco ^a   Busso, C E ^a   Bellver, J ^a   Alama, P ^a   Garrido, N ^a,b   Meseguer, M ^a,b   Pellicer, A ^a,b,c   Remohi, J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Fundacion IVI   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

GnRH agonist; GnRH antagonist; IVF outcome; Oocyte donation; Ovarian hyperstimulation syndrome; Recombinant HCG

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRADIOL; ESTRADIOL VALERATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; PROGEFFIK; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; EMBRYO; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; METAPHASE; NORMAL HUMAN; OOCYTE DONATION; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; TREATMENT OUTCOME;

EID: 70449397316     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.06.001     Document Type: Article

References (33)

1. Acevedo B, Gomez-Palomares JL, Ricciarelli E et al. 2006 Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertility and Sterility 86, 1682-1687. (Pubitemid 44781379)
2. Alikani M, Calderón G, Tomkin G et al. 2000 Cleavage anomalies in early human embryos and survival after prolonged culture in vitro. Human Reproduction 15, 2634-2643. (Pubitemid 32000523)
3. Andersen CY, Humaidan P, Ejdrup HB et al. 2006 Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Human Reproduction 21, 2126-2130. (Pubitemid 44303920)
4. Babayof R, Margalioth EJ, Huleihel M et al. 2006 Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction 21, 1260-1265.
5. Balasch J, Tur R, Creus M et al. 1994 Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecological Endocrinology 8, 7-12. (Pubitemid 24116827)
6. Beckers NG, Macklon NS, Eijkemans MJ et al. 2003 Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Journal of Clinical Endocrinology and Metabolism 88, 4186-4192.
7. Bentick B, Shaw RW, Iffland CA et al. 1990 IVF pregnancy after induction of an ovulatory endogenous gonadotrophin surge using an LHRH agonist nasal spray. Human Reproduction 5, 570-572. (Pubitemid 20250624)
8. Buckett WM, Bentick B, Shaw RW 1998 Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin- releasing hormone analogue (buserelin): effective minimal dose. Human Reproduction 13, 811-814. (Pubitemid 28239179)
9. de Jong D, Van Hooren EG, Macklon NS et al. 2001 Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report. Journal of Assisted Reproduction and Genetics 18, 30-33.
10. Eldar-Geva T, Zylber-Haran E, Babayof R et al. 2007 Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation. Reproductive BioMedicine Online 14, 148-154.
11. Emperaire JC, Ruffie A 1991 Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Human Reproduction 6, 506-510.
12. Emperaire JC, Parneix I, Ruffie A 2004 Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. Reproductive BioMedicine Online 9, 22-27. (Pubitemid 38961707)
13. Engmann L, DiLuigi A, Schmidt D et al. 2008 The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertility and Sterility 89, 84-91.
14. Engmann L, Siano L, Schmidt D et al. 2006 GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reproductive BioMedicine Online 13, 639-644. (Pubitemid 44760886)
15. Fauser BC, de Jong D, Olivennes F et al. 2002 Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 87, 709-715. (Pubitemid 34158241)
16. Garrido N, Zuzuarregui JL, Meseguer M et al. 2002 Sperm and oocyte selection and management: experience of a 10 year follow-up of more than 2100 candidates. Human Reproduction 17, 3142-3147.
17. Golan A, Ron-El R, Herman A et al. 1989 Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynecological Survey 44, 430-440. (Pubitemid 19138981)
18. Griesinger G, Kolibianakis EM, Papanikolaou EG et al. 2007 Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertility and Sterility 88, 616-621.
19. Griesinger G, Diedrich K, Devroey P et al. 2006 GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Human Reproduction Update 12, 159-168.
20. Humaidan P, Bungum L, Bungum M et al. 2006 Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online 13, 173-178. (Pubitemid 44207763)
21. Humaidan P, Bredkjaer HE, Bungum L et al. 2005 GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction 20, 1213-1220. (Pubitemid 40796107)
22. Itskovitz JE, Boldes R, Levron J et al. 1991 Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertility and Sterility 56, 213-220.
23. Kol S, Lewit N, Itskovitz JE 1996 Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Human Reproduction 11, 1143-1148.
24. Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. 2005 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction 20, 2887-2892. (Pubitemid 41508652)
25. Lambalk CB, Homburg R 2006 GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution. Human Reproduction 21, 2580-2582. (Pubitemid 44542148)
26. Lanzone A, Fulghesu AM, Villa P et al. 1994 Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertility and Sterility 62, 35-41. (Pubitemid 24198055)
27. Lanzone A, Panetta V, Di Simone N et al. 1989 Effect of gonadotrophin-releasing hormone and related analogue on human luteal cell function in vitro. Human Reproduction 4, 906-909. (Pubitemid 20072553)
28. Lewit N, Kol S, Manor D et al. 1996 Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Human Reproduction 11, 1399-1402. (Pubitemid 26335083)
29. Melo MA, Meseguer M, Garrido N et al. 2006 The significance of premature luteinization in an oocyte-donation programme. Human Reproduction 21, 1503-1507. (Pubitemid 44445028)
30. Olivennes F, Fanchin R, Bouchard P et al. 1996 Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with GnRH antagonist. Fertility and Sterility 66, 151-153. (Pubitemid 26191290)
31. Orvieto R, Rabinson J, Meltzer S et al. 2006 Substituting HCG with GnRH agonist to trigger final follicular maturation - a retrospective comparison of three different ovarian stimulation protocols. Reproductive BioMedicine Online 13, 198-201. (Pubitemid 44207766)
32. Tavaniotou A, Albano C, Smitz J et al. 2002 Impact of ovarian stimulation on corpus luteum function and embryonic implantation. Journal of Reproductive Immunology 55, 123-130. (Pubitemid 34626157)
33. Tesarik J, Hazout A, Mendoza-Tesarik R et al. 2006 Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Human Reproduction 21, 2572-2579. (Pubitemid 44548853)